文献速递肿瘤 PET/CT

18F-FDG PET/CT代谢状态与非小细胞肺癌免疫标志物表达相关性的新见解

New insight on the correlation of metabolic status on 18F-FDG PET/CT with immune marker expression in patients with non-small cell lung cancer.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2019-09-09

结果发现SUVmax在不同EGFR状态、NLR高低组和PLR高低组间差异显著,且与CD8、CD163、Foxp3、PD-1、PD-L1表达相关,提示SUVmax可能预测免疫治疗候选者。

要点

  • SUVmax在不同EGFR状态、NLR高低组和PLR高低组间差异显著。
  • SUVmax与CD8、CD163、Foxp3、PD-1及PD-L1表达显著相关。
  • SUVmax是肺癌患者独立预后因素,并可能预测免疫治疗候选者。

核心结论

  • 本研究揭示代谢变量与肿瘤微环境免疫细胞表达相关,提示18F-FDG PET/CT的SUVmax可能作为选择免疫治疗候选者的潜在预测指标。

主要发现

  • SUVmax在不同EGFR状态、高/低NLR组和高/低PLR组间差异显著(p<0.001、p<0.001、p=0.003)。
  • SUVmax是肺癌患者独立预后因素(p=0.013)。
  • SUVmax与CD8肿瘤浸润淋巴细胞(p=0.015)、CD163肿瘤相关巨噬细胞(p=0.003)、Foxp3调节性T细胞(p=0.004)及PD-1(p=0.003)和PD-L1(p=0.012)表达显著相关。
  • 疾病分期、BMI、SUVmax、MTV、TLG、CD163-TAMs、CD11c-DCs、PD-L1和Tregs与无进展生存期(PFS)显著相关(p<0.001、0.023、<0.001、0.007、0.005、0.004、0.008、0.048、0.014)。
  • 疾病分期、SUVmax、MTV、TLG、CD163-TAMs、CD11c-DCs和PD-L1与总生存期(OS)显著相关(p<0.001、<0.001、0.014、0.012、<0.001、0.001、<0.001)。

临床怎么用

  • 在非小细胞肺癌患者中,可结合18F-FDG PET/CT的SUVmax评估肿瘤代谢状态,辅助判断肿瘤微环境免疫标志物表达及免疫治疗候选筛选。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Metabolic information obtained through 18F-flurodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) is used to evaluate malignancy by calculating the glucose uptake rate, and these parameters play important roles in determining the prognosis of non-small cell lung cancer (NSCLC). The expression of immune-related markers in tumor tissue reflects the immune status in the tumor microenvironment. However, there is lack of reports on the association between metabolic variables and intra-tumor immune markers. Herein, we investigate the correlation between metabolic status on 18F-FDG PET/CT and intra-tumor immunomarkers' expression in NSCLC patients. METHODS: From April 2008 to August 2014, 763 patients were enrolled in the analysis to investigate the role of maximum standardized uptake value (SUVmax) in lung cancer. One hundred twenty-two tumor specimens were analyzed by immunohistochemistry (IHC) to intra-tumor immune cells and programmed death protein ligand 1(PD-L1) expression on tumor cells. The correlation between metabolic variables and the expression of tissue immune markers were analyzed. RESULTS: SUVmax values have significant variations in different epidermal growth factor receptor (EGFR) statuses (wild type vs mutant type), high/low neutrophil-to-lymphocyte ratio (NLR) groups, and high/low platelets-to-lymphocyte ratio (PLR) groups (p < 0.001, p < 0.001, p = 0.003, respectively). SUVmax was an independent prognostic factor in lung cancer patients (p = 0.013). IHC demonstrated a statistically significant correlation between SUVmax and the expression of CD8 tumor-infiltrating lymphocytes (p = 0.015), CD163 tumor-associated macrophages (TAMs) (p = 0.003), and Foxp3-regulatory T cells (Tregs) (p = 0.004), as well as PD-1 and PD-L1 (p = 0.003 and p = 0.012, respectively). With respect to patient outcomes, disease stage, BMI, SUVmax, metabolic tumor volume (MTV), TLG (tumor lesion glycolysis), CD163-TAMs, CD11c-dendritic cells (DCs), PD-L1, and Tregs showed a statistically significant correlation with progression-free survival (PFS) (p < 0.001, 0.023, < 0.001, 0.007, 0.005, 0.004, 0.008, 0.048, and 0.014, respectively), and disease stage, SUVmax, MTV, TLG, CD163-TAMs, CD11c-DCs, and PD-L1 showed a statistically significant correlation with overall survival (OS) (p < 0.001, < 0.001, 0.014, 0.012, < 0.001, 0.001, and < 0.001, respectively). CONCLUSION: This study revealed an association between metabolic variable and immune cell expression in the tumor microenvironment and suggests that SUVmax on 18F-FDG PET/CT could be a potential predictor for selecting candidates for immunotherapy.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Wang Y, Zhao N, Wu Z, et al. New insight on the correlation of metabolic status on 18F-FDG PET/CT with immune marker expression in patients with non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2019. PMID: 31502013. doi:10.1007/s00259-019-04500-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。